Medicinova Stock Performance
| MNOV Stock | USD 2.05 0.08 3.76% |
On a scale of 0 to 100, MediciNova holds a performance score of 8. The company secures a Beta (Market Risk) of -2.27, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning MediciNova are expected to decrease by larger amounts. On the other hand, during market turmoil, MediciNova is expected to outperform it. Please check MediciNova's downside variance, and the relationship between the total risk alpha and daily balance of power , to make a quick decision on whether MediciNova's current price movements will revert.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in MediciNova are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, MediciNova showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (3.76) | Five Day Return 5.13 | Year To Date Return 24.24 | Ten Year Return (31.67) | All Time Return (81.28) |
Last Split Factor 1:10 | Last Split Date 2006-10-31 |
1 | MediciNova stock gains after patent win | 08/30/2024 |
2 | MediciNova Announces Acceptance of Abstract Regarding MN-166 in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS Meeting | 09/03/2024 |
3 | MediciNova Announces Abstract Regarding MN-166 in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS MND | 09/09/2024 |
4 | MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 in Amyotrophic Lateral Sclerosis | 09/30/2024 |
5 | Acquisition by Nagao Hideki of 20000 shares of MediciNova at 1.34 subject to Rule 16b-3 | 10/04/2024 |
6 | MediciNova Announces Update of Phase 23 Clinical Trial of MN-166 in ALS patients at the 2024 Annual NEALS Meeting | 10/23/2024 |
7 | MediciNova Q3 Earnings Snapshot | 11/13/2024 |
8 | MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders | 11/19/2024 |
9 | Acquisition by Beaver Carolyn of 15000 shares of MediciNova at 5.4 subject to Rule 16b-3 | 11/21/2024 |
| Begin Period Cash Flow | 18.5 M |
MediciNova |
MediciNova Relative Risk vs. Return Landscape
If you would invest 146.00 in MediciNova on August 27, 2024 and sell it today you would earn a total of 67.00 from holding MediciNova or generate 45.89% return on investment over 90 days. MediciNova is currently generating 0.8881% in daily expected returns and assumes 8.341% risk (volatility on return distribution) over the 90 days horizon. In different words, 74% of stocks are less volatile than MediciNova, and 83% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
MediciNova Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MediciNova's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as MediciNova, and traders can use it to determine the average amount a MediciNova's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1065
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MNOV | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 8.34 actual daily | 74 74% of assets are less volatile |
Expected Return
| 0.89 actual daily | 17 83% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average MediciNova is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MediciNova by adding it to a well-diversified portfolio.
MediciNova Fundamentals Growth
MediciNova Stock prices reflect investors' perceptions of the future prospects and financial health of MediciNova, and MediciNova fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MediciNova Stock performance.
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0951 | ||||
| Operating Margin | (9.82) % | ||||
| Current Valuation | 62.39 M | ||||
| Shares Outstanding | 49.05 M | ||||
| Price To Earning | (24.69) X | ||||
| Price To Book | 1.90 X | ||||
| Price To Sales | 104.47 X | ||||
| Revenue | 1000 K | ||||
| Gross Profit | 4.04 M | ||||
| EBITDA | (9.88 M) | ||||
| Net Income | (8.57 M) | ||||
| Cash And Equivalents | 65.23 M | ||||
| Cash Per Share | 1.33 X | ||||
| Total Debt | 215.93 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 17.17 X | ||||
| Book Value Per Share | 1.27 X | ||||
| Cash Flow From Operations | (7.43 M) | ||||
| Earnings Per Share | (0.21) X | ||||
| Market Capitalization | 104.47 M | ||||
| Total Asset | 66.27 M | ||||
| Retained Earnings | (415.7 M) | ||||
| Working Capital | 47.9 M | ||||
| Current Asset | 22.73 M | ||||
| Current Liabilities | 1.49 M | ||||
About MediciNova Performance
Evaluating MediciNova's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if MediciNova has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MediciNova has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.17) | |
| Return On Capital Employed | (0.16) | (0.17) | |
| Return On Assets | (0.13) | (0.14) | |
| Return On Equity | (0.14) | (0.14) |
Things to note about MediciNova performance evaluation
Checking the ongoing alerts about MediciNova for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MediciNova help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MediciNova is way too risky over 90 days horizon | |
| MediciNova appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 1000 K. Net Loss for the year was (8.57 M) with profit before overhead, payroll, taxes, and interest of 4.04 M. | |
| MediciNova currently holds about 65.23 M in cash with (7.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.33. | |
| MediciNova has a poor financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders |
- Analyzing MediciNova's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MediciNova's stock is overvalued or undervalued compared to its peers.
- Examining MediciNova's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MediciNova's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MediciNova's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MediciNova's stock. These opinions can provide insight into MediciNova's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for MediciNova Stock Analysis
When running MediciNova's price analysis, check to measure MediciNova's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MediciNova is operating at the current time. Most of MediciNova's value examination focuses on studying past and present price action to predict the probability of MediciNova's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MediciNova's price. Additionally, you may evaluate how the addition of MediciNova to your portfolios can decrease your overall portfolio volatility.